Nexsen and FlashDx Formed Joint Venture for GBS Testing
The partners will commercialize an enhanced molecular diagnostic for Group B Streptococcus to improve antenatal screening.
Updated on Sept. 25, 2026 in Biotech
Live Poll
Should medical diagnostic companies prioritize faster global market expansion for new diagnostic tests?
Nexsen Limited and FlashDx Shenzhen have signed a non-binding term sheet to establish a 50:50 joint venture. The partnership aims to integrate a Nexsen-developed sample-preparation enhancement into FlashDx’s existing CE-marked molecular test for Group B Streptococcus.
Why it matters
The venture seeks to improve diagnostic sensitivity at low bacterial levels for hospital and intrapartum testing. This effort focuses on expanding access to advanced molecular screening across the Asia-Pacific region.
The venture combines FlashDx's existing CE-marked manufacturing technology with a Nexsen-engineered sample-preparation process. This modification targets increased detection accuracy for Group B Streptococcus in clinical settings.
The players
Nexsen Limited
A biotechnology firm focused on developing sample-preparation enhancements and diagnostic regulatory strategies.
FlashDx Shenzhen
A diagnostics manufacturer that develops molecular testing platforms and holds existing regulatory approvals in the European market.
The details
The collaboration leverages FlashDx’s established molecular diagnostic platform, which already holds CE marking—a certification indicating compliance with European health, safety, and environmental protection standards. Nexsen will contribute a proprietary sample-preparation enhancement, a technique designed to isolate pathogens more effectively from complex clinical specimens. By optimizing this front-end process, the developers aim to improve sensitivity at low bacterial loads. Nexsen will lead and fund the regulatory pathway for the enhanced system.
Timeline
September 25, 2026: The companies announced the signing of the term sheet.
The Tech Race
The joint venture aligns its clinical validation and product roadmap with the requirements of the European Union In Vitro Diagnostic Medical Devices Regulation. This move positions the partnership to compete in the regional diagnostic landscape by bridging proprietary sample-prep improvements with established manufacturing scale.
The enhanced diagnostic is intended for hospital and intrapartum testing environments, with initial market entries prioritized for Hong Kong and India. Nexsen has indicated plans to pursue both US FDA 510(k) clearance and conformity under European standards.
The takeaway
The partnership demonstrates a targeted effort to refine pathogen detection sensitivity for antenatal screening. Interested parties should monitor the companies' regulatory filings for official clearance status in the US and the European Union.
Further reading
For broader trends in diagnostic development, explore our Biotech coverage.
Live Poll
Should medical diagnostic companies prioritize faster global market expansion for new diagnostic tests?
